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Multiple myeloma (MM) is a hematological malignancy, which remains incurable because most patients eventually
relapse or become refractory to current treatments. Due to heterogeneity within the cancer cell microenvironment,
cancer cell populations employ a dynamic survival strategy to chemotherapeutic treatments, which frequently results
in a rapid acquisition of therapy resistance. Besides resistance-conferring genetic alterations within a tumor cell
population selected during drug treatment, recent findings also reveal non-mutational mechanisms of drug
resistance, involving a small population of “cancer stem cells” (CSCs) which are intrinsically more refractory to
the effects of a variety of anticancer drugs. Other studies have implicated epigenetic mechanisms in reversible
drug tolerance to protect the population from eradication by potentially lethal exposures, suggesting that acquired
drug resistance does not necessarily require a stable heritable genetic alteration. Clonal evolution of MM cells and the
bone marrow microenvironment changes contribute to drug resistance. MM-CSCs may not be a static population and
survive as phenotypically and functionally different cell types via the transition between stem-like and non-stem-like
states in local microenvironments, as observed in other types of cancers. Targeting MM-CSCs is clinically relevant, and
different approaches have been suggested to target molecular, metabolic and epigenetic signatures, and the self-
renewal signaling characteristic of MM CSC-like cells. Here, we summarize epigenetic strategies to reverse drug resistance
in heterogeneous multiple myeloma.
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Multiple myeloma (MM) is a form of hematological ma-
lignancy, which originates in the bone marrow (BM),
accounting for 10% of hematological malignancies and 1%
of the total cancer occurrence worldwide [1]. The annual
incidence rate of MM in Europe alone is expected to be
4–6 cases/100,000 people/year mostly affecting older
population with a median age of 63–70 years old [2].
MM is a heterogeneous disease that arises as a result of
several disrupted cancer pathways, in particular those that* Correspondence: wimk.vandenberghe@gmail.com; muriel.cuendet@unige.ch
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and stimulate neoangiogenesis and osteoclastogenesis [3].
An excessive accumulation of myeloma PCs in the BM
outperforms normal osteoblasts, which results into severe
bone pain and contributes to the destruction of normal
BM tissues [4, 5]. As a consequence, a set of defined symp-
toms appear in MM, which include excess of monoclonal
PCs in the BM (>10%), monoclonal M proteins in the
serum and/or urine, and myeloma-related impairments
known as CRAB: C (calcium elevation), R (renal deficiency),
A (anemia), and B (bone damage). Overexpression of sur-
face antigens such as CD54, LFA-1, and CD56 by MM cells
allows them to have complex and mutual interactions be-
tween the malignant PCs and the BM microenvironment.
This promotes the secretion of paracrine cytokines, whichle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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genesis [6].
MM pathogenesis remains poorly understood, and the
clinical response differs among MM patients due to the
inter-individual variability and to the heterogeneous na-
ture of the disease. Treatment options therefore vary
based on the (epi)genetic profile of the MM patient,
which are divided into high and standard risks. Modifi-
cations in the DNA sequence, compromising chromo-
somal transformations, deletions, and point mutations
are thought to be crucial for the malignant transform-
ation of PCs leading to MM [7]. However, the stratifica-
tion of higher risk group from the lower risk group is
ambiguous due to the lack of universally acclaimed
prognostic markers representing the exact molecular
heterogeneity of this disease.
Epigenetic hallmarks of MM
Recent studies indicated that in addition to genetic aber-
rations, epigenetic modifications directly contribute to
MM development [8–13] (Fig. 1). Mechanisms of these
modifications include the effects of microRNAs and
those of polycomb proteins, DNA methylation, histone
modifications, and chromatin remodeling [14–16]. In
addition, genetic mutations of epigenetic modifier en-
zymes, and histone proteins identified by whole-exome
sequencing approaches, further expand the epigenetic
heterogeneity in MM [17] (Table 1). It is currently well
known that the development of MM involves a slow
progression of earlier events consisting of monoclonal
gammopathy of undetermined significance (MGUS)Fig. 1 Epigenetic changes of specific target genes in MM related to cancerfollowed by asymptomatic MM, which progressively
evolves to symptomatic MM [18]. In contrast to other
hematological malignancies such as chronic lymphoid
leukemia (CLL), MM is not derived from one single
driver mutation, suggesting that MM is more heteroge-
neous in disease manifestation [19, 20]. Furthermore,
the spectrum of epigenetic modifier mutations in mye-
loma is broad with no single mutation present in a large
proportion of patients [17]. All stages of MM (from
MGUS to MM pathogenesis) share many features of a
slow accumulation of cytogenetic abnormalities like mu-
tations/deletions of chromosomal regions. Moreover, the
frequency of mutations in epigenetic modifier genes en-
coding histone methyltransferases, histone acetyltrans-
ferases, and DNA (hydroxyl)methylation enzymes is
significantly increasing upon cancer treatment [17].
Thus, from a basic biology standpoint, genetic alter-
ations accompanied by epigenetic ones are the driving
forces behind the MM pathogenesis [21]. Extensive
research has shown that overall genome-wide hypome-
thylation pattern in cancer cells may lead to the reactivation
of transposable elements and transcription modification of
silenced genes [11, 22]. In contrast, DNA hypermethylation
is responsible for the silencing of tumor suppressor genes
in a variety of human malignancies, including MM [11].
The most important epigenetic change observed in MM is
the global hypomethylation, which is associated with a poor
disease prognosis [23]. Heuck et al. showed that myeloma-
genesis involved stage-specific alterations in DNA methyla-
tion suggesting that this phenomenon could be useful for
distinguishing normal PCs from MGUS cells [9]. They alsohallmarks (based on [8–16, 130, 131])
Table 1 Summary of genetic mutations in epigenetic writer-
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terized by a hypomethylation status of tumor suppressor
genes of B cells, when compared to normal PCs, the later
stages were distinguished by a predominant hyperme-
thylation reaching the maximum level in relapsed
cases [9, 24, 25]. These findings indicate that an early
demethylation in repetitive elements may be a poten-
tial destabilizing factor in MM pathogenesis, an effect
that could promote secondary genetic events leading
to the development of a full-blown disease [9]. Fur-
thermore, gene-specific hypermethylation in 77 genes
has also been identified during the transition ofMGUS to MM [24, 25]. These genes are mostly tumor
suppressor genes involved in developmental, cell cycle, and
transcription regulation pathways [24, 25]. In MM patients,
promoter hypermethylation of certain tumor suppressor
genes including p15, p16, VHL, XAF1, IRF8, TP53,
CDKN2A, CDKN2B, DAPK, SOCS1, CDH1, PTGS2,
CCND2, and DCC was shown [26–33]. Of interest, DNA
hypermethylation of the cell cycle inhibitors p15 and p16,
cyclin-dependent kinase inhibitor 2A (CDKN2A), and
TGFBR2 has been associated with poor prognosis in MM
patients [27, 32, 34, 35]. Additionally, the most prominent
DNA hypermethylation changes were observed in the 15%
of patients with t(4;14) translocations, where the 4p16 break
point occurred to the 5′ intron of multiple myeloma SET
domain (MMSET), causing MMSET overexpression [36].
The major determinants of physiological DNA (hydro-
xy)methylation levels are the DNA methyltransferase
(DNMT) enzymes [37], including DNMT1, DNMT3A
and DNMT3B [38, 39], and DNA hydroxymethylase ten-
eleven translocation (TET) enzymes. Whole-exome se-
quencing approaches in MM have recently identified
various DNMT3A and TET2 mutations in MM [17, 40]
(Table 1). However, the full extent of their involvement
in the pathogenesis of MM disease and high risk behav-
ior remains unclear [41]. Typically, transformation into
MM is accompanied by progressive hypermethylation
with maximum methylation seen in relapsed disease.
Furthermore, it has been shown that the expression of
DNMT1 within PCs from MM patients increased pro-
gressively and significantly through the disease course
when compared to healthy PCs [42]. In contrast,
DNMT3A and DNMT3B de novo methyltransferases
were found to be underexpressed in both MGUS indi-
viduals and MM patients when compared to DNMT1
expression level [42, 43]. Although MM is characterized
by widespread alterations in DNA methylation, DNA
hydroxymethylation has also been observed in tran-
scribed genes [43]. The cause of this aberrant expression
of DNMTs is still unknown but it may be linked to the
progressive increase in cell proliferation activity occur-
ring in the various stages of the disease [44, 45]. It is
already known that the expression level of DNMTs is
“cell cycle” dependent and is elevated in cells with high
proliferation rates [46, 47]. Altogether, DNA methylation
changes in MM involve dynamic interplay of multiple
signaling cascades, microRNAs (miRNAs) and non-
coding RNA with DNMT and TET activities [48].
In contrast to DNA methylation, the landscape of his-
tone modifications is more dynamic and constantly
evolving [49]. Histones, and their modifications, are crit-
ical components of cellular programming and epigenetic
inheritance. Structural changes in active euchromatin or
silenced heterochromatin are controlled by chromatin
writer, reader, and eraser enzyme complexes. They
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along the DNA or reversibly modify (acetylation, phos-
phorylation, methylation, ubiquitination, glycosylation,
sumoylation) histones on lysine, arginine, serine, or
threonine residues of amino-terminal histone tails and
establish specific chromatin states, which are involved in
transcription regulation [50]. Recently, exome sequen-
cing in MM has uncovered novel driver mutations in
linker histones and multiple chromatin-modifying writer-
reader-eraser enzymes, including H(D)MTs, HATs, ATP
remodeling, and chromodomain proteins, spurring high
interest how such mutations change enzyme activities or
histone modification patterns and gene expression pat-
terns in MM [16, 49, 51–53] (Table 1).
Histone deacetylases (HDACs) are dysregulated in
MM with an aberrant overexpression of class I HDACs.
This is correlated to a reduced overall survival of pa-
tients with MM [54]. MM cell lines also showed a tran-
scriptional upregulation of the histone methyltransferase
(HMT) enhancer of zest homolog 2 (EZH2) as com-
pared to healthy PCs which do not express EZH2 [55].
EZH2 belongs to a polycomb repressive group protein 2
(PRC2) complex that mediates silencing of gene tran-
scription at the chromatin level through its HMT activity
[56]. H3K27me3 is known to be methylated by EZH2
[56]. The increased EZH2 expression in MM cell lines
may be mediated by interleukin 6 (IL6) in growth factor-
dependent cell lines, caused by IL6-dependent c-Myc or
Stat3 transcription factor activation controlling EZH2
transcription or via posttranscriptional miR-26a regula-
tion [55, 57, 58]. Several studies have demonstrated the
association between IL6 and proliferation response in
MM cell lines [58–60]. In contrast to normal PCs that
do not express EZH2, IL6 stimulation induced EZH2
protein expression in growth factor-dependent cell lines,
while EZH2 was constitutively expressed in growth
factor-independent cell lines [55]. The increased expres-
sion of EZH2 correlated with proliferation and B cell ter-
minal differentiation [55].
Furthermore, the HMT MMSET protein is upregu-
lated in all cases of MM with t(4;14) (p16;q32) transloca-
tions, accounting for approximately 15–20% of all
patients with a poor prognosis [61, 62]. The HMT
MMSET protein functionally interacts with corepressors
and HDACs [63], catalyzing H4K20 trimethylation gene
and loss of histone acetylation [63, 64]. Using the latest
in Orbitrap-based technology, top-down mass spectrom-
etry in MM patients with high and low MMSET expres-
sion has identified complex combinatorial H3 K14/K23
acetylation control of trivalent H3 K9/K27/K36 methyla-
tion marks [51, 52].
Additionally, MMSET enhances the function of HDAC
1 and 2, and the histone demethylase LSD1, suggesting
that it is a component of corepressor complexes [63, 65].Moreover, shRNA-mediated knockdown of MMSET was
associated with the viability of MM cells [63]. This sug-
gests a possible biological role of MMSET in malignant
cell growth. Interestingly, MMSET plays a major role in
constitutive activation of NF-κB, which is frequently
deregulated in MM, by directly interacting with it and
recruiting NF-κB target gene promotors, such as IL6,
IL8, VEGFA, cyclin D, and Bcl-2 [66]. This leads to an
elevation of histone H3K36me2 and H3K36me3 marks
at the promoters resulting in their activation [66].
MiRNAs play a crucial role in the regulation of
different cell functions, including cell differentiation, de-
velopment, and apoptosis [67]. High throughput and
functional studies have demonstrated aberrant miRNA
expression in several human malignancies, where they
can act as oncogenic molecules or as tumor suppressors,
depending on their target transcripts [68–71]. MiRNAs
also interact with important epigenetic regulators in-
volved in the pathogenesis of MM. For example, inacti-
vation of the tumor-suppressive miR-194-2192 cluster
and miR-203 is associated with the pathogenesis of MM
[72, 73]. These studies suggested that these miRNAs tar-
get the IGF pathway, preventing enhanced migration of
PCs into BM. Furthermore, they are positive regulators
for p53 and their downregulation plays an important
role in MM development [74]. Pichiorri et al. compared
the expression profile of miRNA in 49 MM cell lines, 16
BM CD138+ isolated from MM patients and 6 from
MGUS patients, demonstrating that a common miRNA
signature was associated with the multistep transform-
ation process of MM [74]. Additionally, comparison of
MGUS and MM samples with normal PCs, highlighted
important miRNAs, including miR-32 and miR-17-92
cluster (located on chromosome 13), which were only
upregulated in MM cells [75–77]. These miRNAs down-
regulated the expression of SOCS-1, which is frequently
silenced in MM and plays an important role as inhibitor
of IL6 signaling. MM patients with the deletion present
on chromosome 13 showed a reduced survival rate [78].
Finally, miRNA expression may be regulated by DNA
methylation and histone modifications [70]. Global
miRNA suppression in MM could be due to hyperme-
thylation of miRNA, such as miR-152, miR-10b-5p, and
miR-34c-3p [79]. Re-expression of these miRNAs led to
the suppression of oncogenes, inhibition of proliferation,
and induction of apoptosis in MM cells, which suggested
that miRNAs could act as potential tumor suppres-
sors in this malignancy [79]. However, the mecha-
nisms that control the expression of miRNAs are still
mainly unknown.
Epigenetic hallmarks of MM cancer stem cells
The most detailed characterizations of epigenetic alter-
ations have been conducted in the whole cancer cell
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novel paradigm that tumors are composed of heteroge-
neous cell populations, namely tumoral cells and cancer
stem cells (CSCs), imposes on the scientific community
to address the specific epigenetic modifications in each
cell population. In this part, the recent discoveries made
regarding epigenetic modifications in CSCs, with a par-
ticular focus on MM, will be discussed.
The CSCs theory hypothesizes that a subset of tumor
cells exhibits self-renewal properties and differentiation
capabilities and is equipped with detoxification tools,
such as ABC efflux transporters and aldehyde dehydro-
genases [80], rendering those cells, named CSCs, highly
resistant. CSCs are believed to be capable of replenishing
the tumor and to be responsible for tumor relapse [81].
Using stem cell markers, including but not limited to
CD24, CD34, CD44, CD133, and ALDH1, CSCs have
been identified in virtually all cancers. However, al-
though these CSCs markers have been demonstrated to
identify cells capable of recapitulating the tumor in im-
munodeficient mice, heterogeneous cell populations
have also been identified based on the use of these cell
markers, suggesting that parental cells might undergo
some changes during tumor progression [15]. For this
reason, it has been suggested that CSCs should be iden-
tified based on functional assays. This stimulated a de-
bate on the origin of CSCs and their role in tumor
progression. Lineage tracing experiments conducted in
adult murine normal stem cells (NSCs) demonstrated
that NSCs exhibiting specific mutations represent the
cancer cells of origin in skin, colon, leukemic, and brain
tumors [15]. However, other reports indicated that CSCs
can originate from more committed cells that acquire
stem cell features, including self-renewal and differenti-
ation capabilities [15]. This uncertainty in the origin of
CSCs stimulated the search to understand how CSCs
originate, their relationship to NSCs and other tu-
moral cells.
In order to understand the differences between CSCs and
NSCs or between CSCs and tumoral cells, gene expression
and transcriptional profiles were characterized and com-
pared in each cell type. Developmental pathways, such as
Hedgehog (HH), Notch, and Wnt/β-catenin, which control
self-renewal and differentiation, were found to be exten-
sively deregulated and subject to epigenetic alterations in
CSCs. These pathways play pivotal roles in embryonic and
tissue development. They are specifically involved in the
regulations of NSCs, cell fate determination, and stem cell
maintenance. Their deregulation contributes directly to
tumor development, resistance, and metastasis. Epigenetic
mechanisms involved in the regulation of CSCs, NSCs, and
tumoral cells were investigated, and important observations
have been made linking epigenetic alterations to survival
advantages, tumor initiation, and resistance [15, 82].HH signaling pathway is involved in the regulation of
stem cell proliferation in various tissues, and alterations
have been shown to contribute to tumor development
[83, 84]. This pathway starts by the binding of a HH lig-
and to the patched-1 (PTCH-1) receptor, which results
in the activation of smoothened (SMO), a transmem-
brane receptor. SMO, in turn, activates a family of tran-
scription factors named GLI, which ultimately leads to
the activation of target genes [84]. HH ligand promoted
MM-CSCs (CD138− cells) expansion with no effect on
differentiation; whereas, HH pathway blockade with
cyclopamine inhibited MM-CSCs expansion, diminished
the clonal capacity of the MM cell lines NCI-H929 and
KMS12, and decreased the CD138− population through
the induction of PC differentiation, suggesting that HH
signaling plays a key role in the maintenance of MM-
CSCs [83]. Various epigenetic variations of the HH
signaling pathway have been described [85]. PTCH-1
promoter hypermethylation has been reported in several
cancers, including gastric, ovarian, and breast cancers,
causing a downregulation of the active form of the
tumor suppressor PTCH-1 [85]. Treatment with 5-
azacitidine (AZA) resulted in the unmethylation of
PTCH-1 promoter, upregulation of PTCH1 expression,
and apoptosis in gastric cancer cell lines [85]. Further-
more, the promoter HH-interacting protein (HHIP), an-
other negative regulator of the HH signaling pathway,
was found hypermethylated in liver cancer and pancre-
atic tumors, but no methylation was detected in adjacent
healthy tissue (Table 2) [85]. In contrast, HH promoter
is methylated in normal gastric tissue, but not in gastric
carcinoma samples. Taken together, these results shed
light on the importance of epigenetic deregulations in
this pathway where tumor suppressor genes are deacti-
vated and oncogenes activated during tumorigenesis.
Notch signaling is an evolutionary conserved pathway
crucial for normal development and growth. It consists
of five ligands and four transmembrane receptors. The
five ligands are Jagged (JAG)-1 and JAG-2, and Delta-
like (DLL)-1, DLL-3, and DLL-4; and the four trans-
membrane receptors are Notch-1, Notch-2, Notch-3,
and Notch-4. Upon binding of a ligand, a Notch trans-
membrane receptor is cleaved to produce the Notch
intracellular domain (NICD). NICD then translocates to
the nucleus where it acts to upregulate the expression of
Notch target genes related to proliferation, differenti-
ation, and survival [15, 86]. Aberrant activity of the
Notch signaling pathway has been implicated in various
neoplastic processes, including stem cell maintenance,
metastasis, and angiogenesis. In MM, Notch activation
promoted cell proliferation and accelerated disease pro-
gression; whereas, inhibition of Notch induced apop-
tosis, sensitized cells to chemotherapy, and prevented
MM-induced osteoclast activation [87]. These studies
Table 2 Summary of key epigenetic modifications found in MM and their therapeutic agent when available
Cancer cells Epigenetic target/pathway Epigenetic alteration Therapeutic agent Reference
Gastric PTCH-1/HH Hypermethylation 5-AZA [85]
Liver, pancreatic HHIP/HH Hypermethylation [85]
MM JAG-2/Notch Hyperacetylation [88]
MB HES1/Notch miRNA-199b-5p 5-AZA [89]
Colon Notch1/Notch miRNA-34a [90]
MM β-catenin/Wnt Hypermethylation [94]
MM E-cadherin/Wnt miRNA-23A [16]
MM HDACs acetylation PNB [147]
MM HDAC6 acetylation RCL [143]
5-AZA 5-azacytidine, MB medulloblastoma, MM multiple myeloma, PNB panobinostat, RCL ricolinostat
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ing MM-CSCs and in disease progression.
Epigenetic modifications affect the Notch signaling
pathway at multiple levels, including ligands, receptors,
and downstream effectors. In MM, the Notch ligand
JAG-2 has been found overexpressed and the JAG-2
promoter region is aberrantly acetylated in MM cell
lines and patient samples, an effect inflicted on histone
acetylation and regulated by HDACs. Decreased SMRT
levels were found in MM cell lines and patient samples,
which resulted in an upregulation of Notch signaling.
SMRTs are corepressors that typically recruit HDACs to
promoter regions. The restoration of SMRT function in-
duced JAG-2 downregulation as well as MM cell apop-
tosis. These results indicate a correlation between the
acetylation status of the JAG-2 promoter and reduced
levels of the SMRT corepressors in MM cell lines
(Table 2) [88]. Notch pathway is also subject to regula-
tion by miRNAs, which have been implicated in tumor
growth, invasion, and metastasis. For instance, miRNA-
199b-5p was found to negatively regulate HES1, a tran-
scription factor involved in Notch signaling, an effect
that negatively regulated the proliferation of medullo-
blastoma (MB) cells. In addition, overexpression of
miRNA-199b-5p inhibited the expression of several stem
cell specific genes, decreased the MB (CD133+) stem cell
subpopulation, and inhibited the engraftment of MB
cells in nude mice. In an analysis of 61 MB patients,
miRNA-199b-5p expression was significantly higher in
non-metastatic cases than that in metastatic ones and
correlated positively with better overall survival. These
data showing the downregulation of miRNA-199b-5p in
metastatic MB suggest a potential silencing mechanism
through epigenetic or genetic alterations. The use of 5-
aza-2′-deoxycytidine, a DNA methylation inhibitor, re-
sulted in a lower miRNA-199b-5p expression in a panel
of MB cell lines, indicating an epigenetic mechanism of
regulation of Notch in those cells (Table 2) [89]. In
addition, microRNA-34a was shown as a tumorsuppressor that regulated cell fate in early-stage dividing
colon CSCs. Differentiating progeny exhibited higher
levels of miRNA-34a; whereas, self-renewing CSCs
displayed low levels. Interestingly, the balance between
self-renewal and differentiating progeny was altered by
miR-34a loss of function and gain of function experi-
ments both in vitro and in vivo (Table 2). This
phenomenon was found to be mediated by the seques-
tering actions of miR-34a on Notch1 mRNA, an effect
that produced a threshold-like behavior where a Notch
signal level determined self-renewal or differentiation.
These findings demarcated an interesting feature in
which miRNA regulated cell fate in CSCs [90].
The Wnt/β-catenin signaling pathway is involved in
the regulation of self-renewal and differentiation of stem
cells in several organs, including the bone marrow, skin,
and intestinal crypt. This pathway includes 19 ligands
and 10 receptors. The activation of the canonical path-
way causes an accumulation of β-catenin in the cyto-
plasm, which in turn translocates to the nucleus and
alters the expression of Wnt target genes. Aberrant Wnt
signaling activity has been implicated in the develop-
ment of several solid and hematological malignancies
[91]. In MM, β-catenin was found to be constitutively
activated, and the disruption of the active form of
β-catenin appears as a promising therapeutic strategy in
MM. The inhibition of Wnt/β-catenin downregulated
the expression of Wnt target genes, induced cell death,
inhibited tumor growth, and prolonged survival in
mouse xenograft models [92]. This effect has been ob-
served using either small molecules or siRNA directed
towards β-catenin [91, 93]. Epigenetic dysregulation of
the Wnt/β-catenin pathway has been demonstrated in
MM. Gene silencing hypermethylation of multiple Wnt
inhibitors (SFRP2, SFRP3, SFRP5, DKK3, APC, and
WIF1) and of E-cadherin, an intracellular adhesion
molecule responsible for cytoplasmic anchoring of
β-catenin, were associated with constitutive activation of
Wnt signaling in MM cells (Table 2) [94]. Furthermore,
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expression in lung cancer cells has been reported to be
upregulated in MM. In addition, the promoter of
miRNA-203, a direct inhibitor of the Wnt pathway that
is frequently downregulated in MM, has been found
hypermethylated in MM. In contrast, miRNA-21 and
miRNA-200A were upregulated in MM; a situation that
points out that the function of miRNA is context and
cell type dependent (Table 2) [16].
MM hallmarks of therapy sensitivity or drug resistance
Despite of the new therapeutic strategies for MM, in-
cluding conventional chemotherapeutic agents, such as
vincristine and doxorubicin, autologous stem cell trans-
plant and novel agents such as bortezomib, thalidomide,
and lenalidomide, MM remains predominantly incurable
[95–97]. Depending on their stratification, patients are
often subjected to treatments with frontline treatment
options. The European medicines agency (EMA) con-
siders oral combinations of glucocorticoids (prednisone),
proteasomal inhibitors (thalidomide), and alkylating
agents (melphalan) as a frontline therapy often followed
by autologous transplantations [98]. Frontline therapies
along with autologous transplantation have tremen-
dously improved MM patients overall survival rate of 5
to 7 years, but MM patients often develop relapse over
time and die of the disease in the refractory stage of
treatment. There are several mechanisms that may play
a role in MM resistance, including the bone marrow
(BM) microenvironment, growth factors, genetic muta-
tions, deregulated signaling pathways (e.g., multidrug re-
sistance (MDR) genes, anti-apoptosis), clonal evolution
of MM cells, and epigenetic gene inactivation [99].
Many MM relapsing patients who become resistant to
treatment reveal increased expression of the MDR pro-
tein [100, 101]. MDR refers to a pleiotropic resistance to
several structurally unrelated chemotherapeutic agents
after exposure to a single cytotoxic drug [102]. Goldie
and Coldman have hypothesized that the cause for this
phenomenon is that a small number of potential resist-
ant cells may be already present at diagnosis (before
treatment) or may develop during treatment through
spontaneous mutations, which later overgrow the sensi-
tive cell population under the selective pressure of cyto-
toxic drugs [103]. MM has been shown to be generally
MDR-negative at diagnosis. Almost 6% of newly diag-
nosed MM patients with no prior therapy had weakly
expressed MDR markers. Relapsed MM patients are as-
sociated with a high expression of MDR 1 gene (MDR1,
43%) and P-glycoprotein (P-gp, 50–83%) [104]. P-gp is
the first known member of ATP-binding cassette (ABC)
transporter superfamily, which acts as an ATP-
dependent efflux pump and is encoded by MDR1 gene
[105]. The interaction of P-gp with its substrates resultsin the efflux of the substrates (e.g., doxorubicin, alka-
loids) from the intracellular space to the extracellular
space which causes decreasing of therapeutic efficacy
[106]. Clinical trials with several P-gp inhibitors have
demonstrated an increase of intracellular concentra-
tions of affected drug, although the effects have been
modest due to the lack of specificity and potency of
those inhibitors [107].
Also, the BM microenvironment plays a fundamental
role in drug resistance by regulating cell contacts be-
tween MM and BM stromal cells (BMSCs) and fibronec-
tin adhesion, leading to cell survival, migration, and cell
proliferation [108]. The mechanisms which lead to re-
sistance due to the BM microenvironment in MM are
soluble factor-mediated drug resistance (SFM-DR), in-
cluding IL6 and cell-adhesion mediated drug resistance
(CAM-DR), involving adhesion molecules (β1 integrins)
[109]. Moreover, it has been described that MM cells
express the receptor activator of NFκB (RANK) mRNA
[110], and BMSCs and osteoblasts express the
corresponding RANK ligand (RANKL) [111]. Binding of
RANKL to RANK activates different signal transduction
pathways in osteoclasts, including mitogen-activated
protein kinase (MEK), extracellular signal-regulated kin-
ase 1/2 (ERK1/2), phosphatidylinositol 3-kinase, (PI3K),
Akt kinase, mammalian target of rapamycin (mTOR),
and transforming growth factor β (TGF-β)-activated kin-
ase [112]. These signaling pathways are crucial for prolif-
eration, survival, apoptosis, and drug resistance in
cancer cells [113]. Furthermore, CSCs identified in MM
[114, 115], also referred to as cancer-initiating cells are
resistant to chemotherapy, due to their ability to self-
renew [116].
Furthermore, epigenetic alterations have been sug-
gested to be involved in chemotherapy resistance in sev-
eral cancer types including MM. Hypermethylation of
tumor suppressor genes, including GPX3, RBP1, SPARC,
and TGFB, may be involved in drug response and inter-
action with the BM [117]. Another study has shown that
MM patients treated with bortezomib have a higher glo-
bal DNA methylation, which is associated with a higher
overall survival (OS) than patients with a low global
DNA methylation [118]. The combination of highly
methylated global genome with low NFKB1 methylation
status defined a specific subset of patients with better
prognosis [118]. Moreover, hypermethylation of CDKN2A,
CDKN2B, TNF, and RB genes are more frequently shown
in relapsed MM patients than in newly diagnosed patients
[9]. Furthermore, Nojima et al. showed that methylation at
the promotor region of RASD1 gene in MM cells was cor-
related with its silencing and with reduced sensitivity to
dexamethasone (DEX) [119]. Treatment of RASD1-
hypermethylated MM cell lines with 5-aza-2′-deoxycytidine
restored the expression of the gene and consequently the
Table 3 Overview of published clinical trial studies of epigenetic
drugs in MM
Epigenetic function Compound Phase Reference
BET inhibitor OTX015/MK-8628 I [158]
BET inhibitor CPI-0610 I [159]






HDAC inhibitor Abexinostat I [159]
HDAC inhibitor Belinostat II [159]
HDAC inhibitor CI-994 II [159]
HDAC inhibitor CUDC-907 I [159]
HDAC inhibitor Entinostat I [159]
HDAC inhibitor ITF2357 II [159]
HDAC inhibitor Panobinostat II [159]




FDA approved [146, 159]




HDAC inhibitor Rocilinostat I/II [159]
HDAC inhibitor Tefinostat I [159]
HDAC inhibitor Valproate I [159]
HDAC inhibitor Vorinostat I/II [159]
HAT inhibitor Curcumin Preliminary
clinical study
[160]
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tin modifications, such as histone methylation, are also in-
volved in mediating chemotherapy resistance in MM. For
example, anticancer drug-induced H3K27 hypermethyla-
tion is associated with CAM-DR in MM cells [120]. This is
induced by H3K27 via inactivating phosphorylation of the
transcription regulator EZH2 at serine 21, leading to the
sustained expression of antiapoptotic genes, such as IGF1,
B cell CLL/lymphoma 2 (BCL2), and hypoxia inducible fac-
tor 1, α subunit (HIF1A) [120].
Finally, the increased frequency of mutations detected
in genes encoding for histone methyltransferases and
DNA methylation modifiers in treated patients, suggests
that these events may either play a role in disease pro-
gression or occur more frequently following exposure to
induction chemotherapy in resistant subclones [17].
Hence, the use of sequencing-based diagnostics in mye-
loma at diagnosis, during cancer therapy and upon re-
lapse may allow to identify potentially prognostic and/or
targetable (epi)genetic lesions and provide potential new
targets for personalized therapeutic strategies. Moreover,
continuous efforts for counteracting the refractory stage
of this disease and drugs with superior efficacy are
urgently needed [121].
Epigenetic strategies to overcome drug resistance in MM
Several studies have shown that beside genetic muta-
tions, epigenetic alterations participated also in tumor
growth and chemotherapy resistance [122, 123]. Epigen-
etic modifications are generally reversible, and this char-
acteristic of allowing the malignant cell population to
revert to a more “normal” state makes them an attractive
therapeutic target. Chromatin-remodeling inhibitors tar-
geting DNMTs, HMTs, HDACs, and bromodomain pro-
teins or combinations thereof are currently being tested
in various clinical trials for both cancer chemotherapies
and cancer chemoprevention [124–126] (Table 3).
For example, DNMT inhibitors 5-aza-2'-deoxycytidine
(decitabine; DAC) and 5-aza-2'-cytidine (AZA) appeared
to be cancer cytostatic and cytotoxic as they trigger cell
cycle arrest and DNA damage [127–129]. In MM cell
lines, AZA showed anti-myeloma activity by p16 re-
expression, caspase and PARP cleavage, and G0/G1-
phase cell cycle arrest [130, 131]. Along the same line,
DAC restored the expression of p15 by DNA methyla-
tion and induced a G0/G1- and G2/M-phase arrest
linked with p21 and p38, respectively [132]. In addition,
antiapoptotic pathways involving IL6 and NF-κB were
suppressed by AZA [133]. Finally, latest investigations
on the MM epigenome using genome-wide methylation
arrays demonstrated the therapeutic benefit of DNMT
inhibitors to reverse bortezomib or glucocorticoid drug
resistance [101]. For example DNA hypermethylation in
CDKN2A, CDKN2B, TNF, and RB genes has beendetected more frequently in relapsed MM patients
treated with bortezomib [101].
Recent studies showed that HDACs are promising tar-
gets for the treatment of MM, whereby significant
in vitro cell death and in vivo tumor regression were de-
tected [134]. The mechanisms by which HDAC inhibi-
tors exert their effects in MM have been characterized
and include the upregulation of cell cycle inhibitors,
regulation of proapoptotic and antiapoptotic proteins,
aggresome pathway activation, and proteasome inhib-
ition. For instance, the HDAC inhibitor suberoylanilide
hydroxamic acid (SAHA)-induced apoptosis in MM and
B cell tumor cells, with increased p21 and p53 protein
levels, dephosphorylation of Rb, and downregulation of
Bcl-2. SAHA-induced cell death in a pattern indicative
of calpain activation, and the calpain inhibitor calpeptin
prevented SAHA-induced cell death, suggesting a mech-
anism by which HDAC inhibitors may exert their
activity in MM [135]. Both SAHA and trichostatin A
(TSA)-induced cell cycle arrest at the G1 phase and en-
hanced the apoptotic effects of TRAIL, a protein that in-
duces apoptosis in MM cells. These effects of SAHA
and TSA on the cell cycle were mediated by the
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transcriptional activity; whereas, the effects on apoptosis
were mediated by the upregulation of Bim, Bak, Bax,
Noxa, and PUMA, and downregulation of Bcl-2, Bcl-X,
and IAPs. Interestingly, the apoptotic effects of TSA
were increased by the proteasome inhibitor, MG132
[136]. Panobinostat (PNB), a hydroxamic acid derivative,
in combination with bortezomib (BTZ), a proteasome
inhibitor, resulted in a synergistic activity against DEX-
sensitive and DEX-resistant MM cells, as well as in pri-
mary patient MM cells. BTZ and DEX are both used in
combination as a first line therapy for MM (Tables 2
and 3) [137]. In the presence of BTZ, PNB induced α-
tubulin hyperacetylation and caused aggresome forma-
tion. These results suggested a potential clinical benefit
of combining proteasome inhibitors with HDAC inhibi-
tors [138]. The precise mechanism of synergy is exerted
by the dual inhibition of the proteasome and aggresome
pathways, which results in increased levels of polyuquiti-
nated proteins leading to cellular stress and apoptosis.
The aggresome pathway is responsible for shuttling ubi-
quitinated proteins for lysosomal degradation. Specific-
ally, proteasome inhibition leads to the accumulation of
ubiquitin protein aggregates. The transport of protein
aggregates along the microtubule network is facilitated
by HDAC6, whose inhibition leads to synergistically in-
creased cellular stress and apoptosis when used in com-
bination with proteasome inhibitors [139]. Although this
has been a central explanation for the synergistic effects,
additional mechanisms have been characterized. For in-
stance, preincubation with a subtoxic concentration of
BTZ appeared to result in synergistic apoptosis induc-
tion in response to sodium butyrate and SAHA, two
established HDAC inhibitors. The mechanism of this syn-
ergy was demonstrated as a BTZ-induced sensitization of
U266 and MM.1S cells to sodium butyrate- and SAHA-
induced mitochondrial dysfunction; caspase 9, 8, and 3 ac-
tivation; and PARP degradation [140]. These effects were
associated with NF-κB inactivation, p53 induction,
caspase-dependent cleavage of p21, p27, Bcl-2, and
X-linked inhibitor of apoptosis, and a marked ROS
generation. Interestingly, the combination of bortezo-
mib/HDAC inhibitors resulted in a pronounced
CD138+ bone marrow cell death from MM patients,
but this effect was not observed in the CD138− cell
population, suggesting a differential effect between tu-
moral PCs and MM-CSCs [140].
Although multiple HDAC inhibitors demonstrated im-
portant anticancer activities preclinically, their clinical
utility has been limited due to adverse effects associated
with pan-HDAC inhibition. Thus, isoform-selective in-
hibition may reduce those side effects. The inhibition of
HDAC3 by knockdown or small-molecule inhibitor
triggered significant MM cell growth inhibition viaapoptosis. Importantly, HDAC3 inhibition, but not
HDAC1 or 2, significantly augmented BTZ-induced
cytotoxicity in vitro, and triggered tumor growth inhib-
ition in a murine xenograft model of human MM, sug-
gesting that HDAC3 represents a promising therapeutic
target for the treatment of MM [141].
Furthermore, several HDAC6 inhibitors demonstrated
important anticancer activities both in vitro and in vivo.
HDAC6 is a zinc-dependent enzyme that belongs to
class II histone deactylases [142]. An important HDAC6
target is α-tubulin, hence the important role of HDAC6
in protein trafficking, cell shape, and migration [142].
For these reasons, HDAC6 emerged as a valuable thera-
peutic target in cancer and other diseases [142]. HDAC6
inhibitors demonstrated strong antiproliferative activity,
induced cell death in several cancer cell lines, and re-
duced tumor mass without overt toxicity [142]. These
HDAC inhibitors include an important drug candidate
termed ricolinostat (RCL). RCL, a hydroxamic acid
HDAC6-selective inhibitor, showed strong anti-myeloma
activity when combined with BTZ or with carfilzomib in
preclinical studies. RCL selectively inhibited HDAC6, in-
duced dose-dependent cell death in several sensitive and
resistant MM cell lines, and triggered synergistic mye-
loma cell cytotoxicity when combined with BTZ or
with carfilzomib both in vitro and in vivo (Table 2)
[143, 144]. These promising results accelerated the exam-
ination of RCL in phase I/II clinical studies in relapsed
and/or refractory (R/R) MM. Phase I clinical trials of
RCL/DEX/lenalidomide in R/R MM demonstrated that
RCL was safe and well-tolerated, and a preliminary exam-
ination showed that RCL exhibited significant antitumor
activity in 55% of tested patients [145]. Phase I and II clin-
ical trials, examining RCL in combination with pomalido-
mide and DEX, or in combination with BTZ and DEX, in
R/R MM are ongoing.
PNB is a non-selective HDAC inhibitor that exerts a
potent activity against all three classes of HDACs (I, II,
and IV) (Table 2). PNB is an oral drug that was recently
approved by the FDA for the treatment of patients with
R/R MM who have previously been treated with at least
two regimens (including BTZ, DEX, or immunomodula-
tory agents) [146]. Clinically, PNB is the first HDAC in-
hibitor to demonstrate a significant improvement in
patients with R/R MM, and is currently prescribed in
combination with BTZ and DEX. In R/R MM patients,
PNB/BTZ/DEX was found to significantly prolong the
progression free survival (PFS) in comparison to pla-
cebo/BTZ/DEX [146]. Importantly, PNB (when com-
bined with BTZ/DEX) reduced the relative risk of death,
relapse, and disease progression by 37% in R/R MM pa-
tients. In addition, PNB resulted in a more than 2-fold
increase of the 2-year PFS, and the median follow-up by
1.15-fold [146]. Furthermore, the near-complete
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higher in the PNB/BTZ/DEX group. Of note, the fa-
vorable results of PNB were consistently detected
across different randomized control trials [147]. In
general, the drug regimen PNB/BTZ/DEX exhibited a
tolerable profile in R/R MM patients. The most fre-
quent adverse effects were hematological, including
thrombocytopenia (67%), lymphopenia (54%), and
neutropenia (35%). The corresponding incidences of
these adverse effects in the placebo group were 31,
40, and 11%. Common non-hematological adverse ef-
fects were also observed and included severe diarrhea
(25%), pneumonia (13%), and peripheral neuropathy
(18%). The corresponding incidences of these adverse
effects in the placebo group were 8, 13, and 15%
[146]. Clinical trials of PNB with carfilzomib or with
lenalidomide/BTZ/DEX are ongoing for R/R MM, and
desirable results are eagerly awaited. In conclusion,
PNB (when combined with BTZ/DEX) appears a well-
tolerated agent in patients with R/R MM and conse-
quently a promising agent.
Conclusions
Recently, outcomes for patients with MM have improved
due to the application of “better developed” and novel
epigenetic therapies. Although epigenetic drugs have sig-
nificant anti-myeloma activity or can restore drug sensi-
tivity [148], it remains unclear whether they can also
restore the precancerous epigenetic state. In addition, in-
hibition of a specific epigenetic modifier may not kill the
malignant CSC clone. Moreover, due to the complexity
and epigenomic heterogeneity of MM cells, epigenomic
profiling of the therapy resistant or sensitive MM cancer
(stem) cell subpopulations may allow to personalize and
optimize MM treatment protocols [149]. Finally, new
combinations of frontline therapies with two or more
epigenetic drugs may reveal additional synergistic or
chemosensitising effects, pending an acceptable control
of side effects [150–153].
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